Last updated: February 12, 2026
What is the current status of clinical trials for Suprofen?
Suprofen is a non-steroidal anti-inflammatory drug (NSAID) initially marketed for ocular and systemic applications. Its primary use was as a topical ophthalmic solution for reducing inflammation and pain post-surgery. Development efforts for oral or systemic uses ceased after patent expirations and safety concerns, but interest persists in specific niche indications.
Key Points:
- Clinical trial activity is limited. The latest registrations or studies date back to the early 2000s, mostly focusing on ophthalmic applications.
- No recent FDA or EMA-approved new indications or formulations for Suprofen.
- Ongoing research appears limited or unpublicized, indicating a decline in development activities.
- Patent landscape shows expiration in the early 2010s, reducing commercial incentives for large-scale trials or new formulations.
How does Suprofen compare to other NSAIDs in clinical trials?
| Aspect |
Suprofen |
Diclofenac |
Ketorolac |
Bromfenac |
| Clinical activity |
Limited since early 2000s |
Ongoing in multiple indications |
Widely used, multiple formulations |
Focus on ophthalmic applications |
| Current trials |
None confirmed |
Multiple ongoing |
Several recent trials |
Mainly marketed products, few trials |
| Approval status |
Discontinued in systemic use |
Approved globally |
Approved worldwide |
Approved for ocular uses |
Suprofen's clinical trail activity has been eclipsed by other NSAIDs with broader indications and more recent research.
What is the market landscape for Suprofen?
Market segments:
- Ophthalmic NSAIDs comprise a niche, with Bromfenac and Ketorolac dominating. Suprofen was historically used but is no longer marketed in many regions.
- Systemic NSAIDs: Suprofen practiced limited systemic use; existing products like diclofenac, ibuprofen, and naproxen overshadow it.
Key Market Data (2022):
- The global ophthalmic NSAID market is valued at approximately USD 2.5 billion, driven by the increasing prevalence of cataracts, glaucoma, and postoperative inflammation.
- Suprofen's market share has diminished due to safety concerns and the expiration of patents.
- Major competitors hold dominant positions: Bromfenac (Xibrom, Prolensa), Ketorolac (Acular, Toradol).
- Price point: Suprofen’s formulations were priced competitively when marketed but are no longer commercially available in most regions.
What are the projections for Suprofen's future in the pharmaceutical market?
Given its limited current activity:
- Patent expiration and safety concerns reduce prospects for new formulations.
- Any resurgence depends on reformulation with improved safety profiles or new indications.
- R&D investment is unlikely without clear advantages over existing NSAIDs or novel delivery mechanisms.
- Market demand for ophthalmic NSAIDs is stable but not expanding rapidly, favoring existing drugs.
Potential niche roles:
- Resurrected via reformulation with targeted delivery systems (e.g., nanoparticle-based eye drops).
- Investigated for anti-inflammatory uses beyond ocular applications, but no active efforts are publicly reported.
Summary of development outlook:
| Scenario |
Likelihood |
Timeline |
Comments |
| No new trials |
High |
0-5 years |
Patent expiry, safety concerns prevail |
| Reformulation for niche use |
Low |
3-5 years |
Requires significant R&D, funding |
| Market replacement |
Very high |
Immediate |
Existing NSAIDs dominate |
Key Takeaways
- Suprofen’s clinical development has largely ceased since early 2000s, with no significant ongoing trials.
- The drug’s market share has been overtaken by newer, safer NSAIDs primarily used in ophthalmology.
- Future growth hinges on reformulation or finding new niche indications, neither of which is imminent based on current activity.
- The global ophthalmic NSAID market remains stable, with existing competitors consolidating the majority of sales.
- Suprofen faces strong barriers due to patent expirations, safety histories, and lack of recent clinical interest.
FAQs
1. Why did Suprofen fall out of favor?
Safety concerns, especially related to systemic absorption and adverse side effects, combined with patent expiration, reduced its competitive edge.
2. Are there any ongoing clinical trials involving Suprofen?
Currently, no public records show active or upcoming trials for Suprofen.
3. Can Suprofen be reformulated for modern use?
Potential exists, but it would require significant investment to improve safety profiles and patent protections.
4. How competitive is the ophthalmic NSAID market?
Dominated by Bromfenac and Ketorolac, with established safety and efficacy profiles.
5. What licensing opportunities exist for Suprofen?
Limited, due to its outdated profile and the availability of alternatives with better safety data.
References
[1] MarketsandMarkets. “Ophthalmic Drugs Market by Product, Application, and Region: Global Forecast to 2027.”
[2] FDA Drugs Database. “Suprofen (Tafazolin/Opthalmic).”
[3] PatentScope. “Patent Expiry Data for NSAIDs.”
[4] Grand View Research. “NSAID Market Size, Share & Trends.”
